Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Molecular scissors cut in on stem cells.

Azvolinsky A.

Nat Med. 2019 Jun;25(6):864-866. doi: 10.1038/s41591-019-0467-6. No abstract available.

PMID:
31086349
2.

Gut checkpoint: A rising cancer treatment may get a boost from intestinal bacteria.

Azvolinsky A.

Nat Med. 2018 Mar 6;24(3):251-253. doi: 10.1038/nm0318-251. No abstract available.

PMID:
29509755
3.

Screening Guideline for Cervical Cancer Recommends Against Human Papillomavirus-Pap Cotesting.

Azvolinsky A.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx256. No abstract available.

PMID:
29155972
4.

Statins for Cancer: Still Uncertain.

Azvolinsky A.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djx109. No abstract available.

PMID:
30053143
5.

The Obesity-Cancer Link: A Growing Connection.

Azvolinsky A.

J Natl Cancer Inst. 2016 Oct;108(10). pii: djw243. No abstract available.

PMID:
27737916
6.

Targeting Tumors' Energy Needs.

Azvolinsky A.

J Natl Cancer Inst. 2016 Sep 14;108(9). pii: djw219. doi: 10.1093/jnci/djw219. Print 2016 Sep. No abstract available.

PMID:
27628660
7.

Erratum: 20 years of Nature Biotechnology research tools.

Azvolinsky A, DeFrancesco L, Waltz E, Webb S.

Nat Biotechnol. 2016 Jun 9;34(6):666. doi: 10.1038/nbt0616-666a. No abstract available.

PMID:
27281426
8.

Erratum: 20 years of Nature Biotechnology biomedical research.

Azvolinsky A, Schmidt C, Waltz E, Webb S.

Nat Biotechnol. 2016 Jun 9;34(6):666. doi: 10.1038/nbt0616-666b. No abstract available.

PMID:
27281425
9.

Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.

Azvolinsky A.

J Natl Cancer Inst. 2016 Jun 2;108(6):djw161. doi: 10.1093/jnci/djw161. Print 2016 Jun. No abstract available.

PMID:
27257028
10.

Unraveling How Obesity Fuels Cancer.

Azvolinsky A.

J Natl Cancer Inst. 2016 Apr 2;108(4). pii: djw116. doi: 10.1093/jnci/djw116. Print 2016 Apr. No abstract available.

PMID:
27038117
11.

20 years of Nature Biotechnology biomedical research.

Azvolinsky A, Schmidt C, Waltz E, Webb S.

Nat Biotechnol. 2016 Mar;34(3):262-6. doi: 10.1038/nbt.3509. No abstract available. Erratum in: Nat Biotechnol. 2016 Jun;34(6):666. Nat Biotechnol. 2016 Jun 9;34(6):666.

PMID:
26963547
12.

20 years of Nature Biotechnology research tools.

Azvolinsky A, DeFrancesco L, Waltz E, Webb S.

Nat Biotechnol. 2016 Mar;34(3):256-61. doi: 10.1038/nbt.3507. No abstract available. Erratum in: Nat Biotechnol. 2016 Jun;34(6):666. Nat Biotechnol. 2016 Jun 9;34(6):666.

PMID:
26963546
13.

Severe asthma gets first biologic in decades.

Azvolinsky A.

Nat Biotechnol. 2016 Jan;34(1):10-1. doi: 10.1038/nbt0116-10. No abstract available.

PMID:
26744963
14.

Ask Early and Often: Offering Better Palliative Care.

Azvolinsky A.

J Natl Cancer Inst. 2015 Dec 27;108(1). pii: djv420. doi: 10.1093/jnci/djv420. Print 2016 Jan. No abstract available.

PMID:
26711665
15.

Breathing easier with combinations.

Azvolinsky A.

Nat Biotechnol. 2015 Nov;33(11):1128-30. doi: 10.1038/nbt.3397. No abstract available.

PMID:
26544137
16.

Diabetics at increased risk of advanced breast cancer.

Azvolinsky A.

Oncology (Williston Park). 2015 Sep;29(9):650. No abstract available.

PMID:
26495509
17.

Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved.

Azvolinsky A.

J Natl Cancer Inst. 2015 Sep 4;107(9). pii: djv268. doi: 10.1093/jnci/djv268. Print 2015 Sep. No abstract available.

18.

Gene therapy 'cure' for blindness wanes.

Azvolinsky A.

Nat Biotechnol. 2015 Jul;33(7):678. doi: 10.1038/nbt0715-678. No abstract available.

PMID:
26153993
19.

Industry chases pan-genotypic and shorter HCV treatments.

Azvolinsky A.

Nat Biotechnol. 2015 Jun;33(6):575-6. doi: 10.1038/nbt0615-575. No abstract available.

PMID:
26057958
20.

First-in-class HIV drug enters phase 3 trials.

Azvolinsky A.

Nat Biotechnol. 2015 May;33(5):439. doi: 10.1038/nbt0515-439a. No abstract available.

PMID:
25965738
21.

Colorectal cancer: to stack or sequence therapy?

Azvolinsky A.

J Natl Cancer Inst. 2015 May 9;107(5). pii: djv138. doi: 10.1093/jnci/djv138. Print 2015 May. No abstract available.

PMID:
25957442
22.

Breast irradiation therapy innovations forgo permanent marks, minimize treatment.

Azvolinsky A.

J Natl Cancer Inst. 2015 Mar 5;107(3). pii: djv067. doi: 10.1093/jnci/djv067. Print 2015 Mar. No abstract available.

PMID:
25745012
23.

Beyond counting: new way to use circulating tumor cells.

Azvolinsky A.

J Natl Cancer Inst. 2014 Oct 13;106(10). pii: dju343. doi: 10.1093/jnci/dju343. Print 2014 Oct. No abstract available.

PMID:
25313232
24.

Identifying cancer mutations as therapeutic targets.

Azvolinsky A.

J Natl Cancer Inst. 2014 Aug 13;106(8). pii: dju276. doi: 10.1093/jnci/dju276. Print 2014 Aug. No abstract available.

PMID:
25122735
25.

Cancer prognosis: role of BMI and fat tissue.

Azvolinsky A.

J Natl Cancer Inst. 2014 Jun 6;106(6):dju177. doi: 10.1093/jnci/dju177. Print 2014 Jun. No abstract available.

PMID:
24907390
26.

Mystery around drug adherence still plagues medical literature.

Azvolinsky A.

Nat Med. 2014 May;20(5):455. doi: 10.1038/nm0514-455. No abstract available.

PMID:
24804741
27.

Cancer risk: the fat tissue-BMI-obesity connection.

Azvolinsky A.

J Natl Cancer Inst. 2014 Apr;106(4):dju100. doi: 10.1093/jnci/dju100. Epub 2014 Mar 31. No abstract available.

PMID:
24685924
28.

Repurposing to fight cancer: the metformin-prostate cancer connection.

Azvolinsky A.

J Natl Cancer Inst. 2014 Feb;106(2):dju030. doi: 10.1093/jnci/dju030. No abstract available.

PMID:
24511112
29.

Academic medical centers fear squeeze from Affordable Care Act.

Azvolinsky A.

Nat Med. 2014 Feb;20(2):106. doi: 10.1038/nm0214-106. No abstract available.

PMID:
24504392
30.

Conjugating antibodies to cytotoxic agents: getting the best of both worlds?

Azvolinsky A.

J Natl Cancer Inst. 2013 Dec 4;105(23):1765-6. doi: 10.1093/jnci/djt354. Epub 2013 Nov 16. No abstract available.

PMID:
24244034
31.

Supreme Court ruling broadens BRCA testing options.

Azvolinsky A.

J Natl Cancer Inst. 2013 Nov 20;105(22):1671-2. doi: 10.1093/jnci/djt342. Epub 2013 Nov 6. No abstract available.

PMID:
24198329
32.

Concerned about HPV-related cancer rise, researchers advocate boosting HPV vaccination rates.

Azvolinsky A.

J Natl Cancer Inst. 2013 Sep 18;105(18):1335-6. doi: 10.1093/jnci/djt260. Epub 2013 Aug 29. No abstract available.

PMID:
23990671
33.

One size does not fit all: personalized immune therapies poised to take center stage.

Azvolinsky A.

J Natl Cancer Inst. 2013 May 1;105(9):583-4. doi: 10.1093/jnci/djt103. Epub 2013 Apr 16. No abstract available.

PMID:
23591459
34.

Diagnostic lens turns to difficult-to-detect ovarian cancer.

Azvolinsky A.

Nat Med. 2013 Feb;19(2):117. doi: 10.1038/nm0213-117. No abstract available.

PMID:
23389592
35.

Cancer vaccines: always a bridesmaid, never a bride?

Azvolinsky A.

J Natl Cancer Inst. 2013 Feb 20;105(4):248-9. doi: 10.1093/jnci/djt019. Epub 2013 Jan 31. No abstract available.

PMID:
23369950
36.

PARP inhibitors: targeting the right patients.

Azvolinsky A.

J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10. No abstract available.

PMID:
23231976
37.

Assessing cancer with a blood draw.

Azvolinsky A.

J Natl Cancer Inst. 2012 Dec 5;104(23):1774-5. doi: 10.1093/jnci/djs495. No abstract available.

PMID:
23213181
38.

Lack of BRCA testing approval creates snag for cancer trials.

Azvolinsky A.

Nat Med. 2012 Sep;18(9):1310. doi: 10.1038/nm0912-1310a. No abstract available.

PMID:
22961142
39.

Cancer stem cells: getting to the root of cancer.

Azvolinsky A.

J Natl Cancer Inst. 2012 Jun 20;104(12):893-5. doi: 10.1093/jnci/djs292. No abstract available.

PMID:
22715190
40.

Long-term breast cancer patient follow-up care.

Azvolinsky A.

Am J Manag Care. 2012 May;18(3 Spec No.):SP127. Review. No abstract available.

PMID:
22642279
41.

Preserving fertility in cancer patients.

Azvolinsky A.

J Natl Cancer Inst. 2012 May 16;104(10):724-5. doi: 10.1093/jnci/djs246. Epub 2012 Apr 27. No abstract available.

PMID:
22544943
42.

Companies hope for rare win with cancer stem cell therapies.

Azvolinsky A.

Nat Med. 2012 Apr 5;18(4):474. doi: 10.1038/nm0412-474a. No abstract available.

PMID:
22481389
43.

Replication termination at eukaryotic chromosomes is mediated by Top2 and occurs at genomic loci containing pausing elements.

Fachinetti D, Bermejo R, Cocito A, Minardi S, Katou Y, Kanoh Y, Shirahige K, Azvolinsky A, Zakian VA, Foiani M.

Mol Cell. 2010 Aug 27;39(4):595-605. doi: 10.1016/j.molcel.2010.07.024.

44.

Highly transcribed RNA polymerase II genes are impediments to replication fork progression in Saccharomyces cerevisiae.

Azvolinsky A, Giresi PG, Lieb JD, Zakian VA.

Mol Cell. 2009 Jun 26;34(6):722-34. doi: 10.1016/j.molcel.2009.05.022.

45.

Origin of tropical American burrowing reptiles by transatlantic rafting.

Vidal N, Azvolinsky A, Cruaud C, Hedges SB.

Biol Lett. 2008 Feb 23;4(1):115-8.

46.

B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, Metzgar MH, Paterson J, Erikson J, Marafioti T, Monroe JG, Atchison ML, Thomas-Tikhonenko A.

J Clin Invest. 2007 Sep;117(9):2602-10.

47.

The S. cerevisiae Rrm3p DNA helicase moves with the replication fork and affects replication of all yeast chromosomes.

Azvolinsky A, Dunaway S, Torres JZ, Bessler JB, Zakian VA.

Genes Dev. 2006 Nov 15;20(22):3104-16.

48.

Supplemental Content

Loading ...
Support Center